Erythropoietin Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (Biologics and Biosimilars), Product, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034

The global erythropoietin drugs market size is expected to reach USD 8.17 billion by 2034, according to a new study by Polaris Market Research. The report “Erythropoietin Drugs Market Size, Share, Trends, Industry Analysis Report: By Type (Biologics and Biosimilars), Product, Application, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The erythropoietin drugs market comprises pharmaceutical agents that stimulate red blood cell production, primarily used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other medical conditions.

The market is experiencing steady growth due to the increasing prevalence of chronic diseases, rising demand for biosimilars, and advancements in drug formulations. Favorable regulatory policies supporting biosimilar approvals and expanding healthcare access in emerging markets present significant opportunities for market expansion.

Key erythropoietin drugs market trends include the development of long-acting formulations, strategic collaborations, and growing investment in research and development. Overall, the market is driven by the need for effective anemia management, cost-effective treatment options, and the continuous evolution of erythropoietin therapies.

Erythropoietin Drugs Market Report Highlights

Based on application, the renal diseases segment dominated the market in 2024, owing to the widespread incidence of chronic kidney disease (CKD). This condition frequently causes anemia due to impaired erythropoietin production in damaged kidneys, creating substantial demand for EPO therapies.

By type, biosimilars are witnessing significant growth due to patent expirations of biologic erythropoietin drugs and increasing demand for cost-effective treatment options. Regulatory support and expanding biosimilar adoption in emerging markets further drive this segment.

In 2024, North America holds the largest share in the erythropoietin drugs market, primarily due to the high prevalence of chronic kidney disease (CKD) and cancer, which often lead to anemia requiring erythropoietin therapy.

The Asia Pacific erythropoietin drugs market is witnessing significant growth, primarily due to the high prevalence of anemia and chronic kidney disease, especially in countries like India and China.

Notable companies include Amgen Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Pfizer Inc.; Novartis AG; Biocon Limited; Teva Pharmaceutical Industries Ltd.; Dr. Reddy’s Laboratories Ltd.; LG Chem Ltd.; Wockhardt Ltd.; Intas Pharmaceuticals Ltd.; Sun Pharmaceutical Industries Ltd.; Celltrion Inc.; Kyowa Kirin Co., Ltd.; and Swedish Orphan Biovitrum AB.

Polaris Market Research has segmented the erythropoietin drugs market report on the basis of type, product, application, and region:

By Type Outlook (Revenue – USD Billion, 2020–2034)

Biologics

Biosimilars

By Product Outlook (Revenue – USD Billion, 2020–2034)

Erythropoietin

Darbepoetin-alfa

By Application Outlook (Revenue – USD Billion, 2020–2034)

Cancer

Renal Diseases

Neurology

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America